New York State Common Retirement Fund Reduces Stock Position in Moderna, Inc. (NASDAQ:MRNA)

New York State Common Retirement Fund cut its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 8.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 364,767 shares of the company's stock after selling 33,365 shares during the period. New York State Common Retirement Fund owned approximately 0.09% of Moderna worth $10,341,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in MRNA. Itau Unibanco Holding S.A. raised its stake in Moderna by 51.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after buying an additional 343 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in Moderna by 0.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock worth $3,099,000 after purchasing an additional 345 shares during the period. Deseret Mutual Benefit Administrators grew its holdings in Moderna by 53.3% in the first quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock worth $32,000 after purchasing an additional 392 shares during the period. Parallel Advisors LLC grew its holdings in Moderna by 11.4% in the first quarter. Parallel Advisors LLC now owns 4,403 shares of the company's stock worth $125,000 after purchasing an additional 451 shares during the period. Finally, Signaturefd LLC grew its holdings in Moderna by 17.4% in the fourth quarter. Signaturefd LLC now owns 3,618 shares of the company's stock worth $150,000 after purchasing an additional 535 shares during the period. 75.33% of the stock is owned by institutional investors.

Analysts Set New Price Targets

MRNA has been the topic of a number of recent research reports. Wells Fargo & Company restated an "equal weight" rating on shares of Moderna in a report on Sunday, July 13th. Royal Bank Of Canada cut their price target on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. William Blair reiterated a "market perform" rating on shares of Moderna in a report on Monday, June 2nd. Cowen assumed coverage on shares of Moderna in a report on Sunday, July 13th. They set a "hold" rating on the stock. Finally, Barclays reiterated an "equal weight" rating on shares of Moderna in a report on Sunday, July 13th. Four research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $46.61.

Moderna Price Performance

Shares of MRNA stock traded down $0.94 on Friday, hitting $31.26. 7,814,334 shares of the stock traded hands, compared to its average volume of 8,967,321. The firm has a market cap of $12.09 billion, a price-to-earnings ratio of -3.58 and a beta of 1.84. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $125.68. The firm has a 50 day simple moving average of $27.91 and a two-hundred day simple moving average of $30.85.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating the consensus estimate of ($2.92) by $0.40. The firm had revenue of $108.00 million for the quarter, compared to the consensus estimate of $130.35 million. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. The company's revenue was down 35.3% on a year-over-year basis. During the same period last year, the firm earned ($3.07) EPS. Sell-side analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.